We hope you find what you’re looking for. You can email us if you need additional help.
VANCOUVER, BC – January 29, 2025 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, GMP-grade psilocybin and MDMA, has completed its largest
Vancouver, British Columbia – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to close a second and final
Vancouver, British Columbia — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is proud to announce that its natural psilocybin extract has
Vancouver, British Columbia–(Newsfile Corp. – January 6, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is pleased to announce the
Vancouver, British Columbia–(Newsfile Corp. – December 17, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Canadian manufacturer of GMP-certified, naturally-derived psilocybin and MDMA, has entered into binding agreements with Psyence Biomedical Ltd.
Vancouver, British Columbia – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in botanical psilocybin and MDMA, is proud to announce that the first group of patients
Vancouver, British Columbia – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping
Vancouver, British Columbia–August 28, 2024 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics pharmaceuticals specializing in botanical psilocybin and MDMA, is pleased to announce the receipt of
Forbes Australia covered Optimi co-founder, JJ Wilson’s, journey toward making Optimi the number one supplier of psilocybin and MDMA in Australia. Read the article here.
Vancouver, British Columbia–August 16, 2024 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the
Regulator Filings
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
